{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sickle-cell-disease/management/management-sickle-cell-trait/","result":{"pageContext":{"chapter":{"id":"2aeac855-0e31-598c-804d-41c8d9bc643f","slug":"management-sickle-cell-trait","fullItemName":"Scenario: Management - sickle cell trait","depth":2,"htmlHeader":"<!-- begin field 1675ed6e-a3b5-4886-b43b-5621d94a151d --><h2>Scenario: Management - sickle cell trait</h2><!-- end field 1675ed6e-a3b5-4886-b43b-5621d94a151d -->","summary":"Covers the management of sickle cell trait in primary care.","htmlStringContent":"<!-- begin item 87b4ca9b-ee27-48d2-ade3-c68fc7b2292d --><!-- begin field 2c2540e8-f63b-4ad5-9501-acbd00886139 --><p>From birth onwards.</p><!-- end field 2c2540e8-f63b-4ad5-9501-acbd00886139 --><!-- end item 87b4ca9b-ee27-48d2-ade3-c68fc7b2292d -->","topic":{"id":"eb346bd0-1df2-5db2-a583-a366e34cfc19","topicId":"cc107f5d-efe6-4625-840e-5c4d4656869b","topicName":"Sickle cell disease","slug":"sickle-cell-disease","lastRevised":"Last revised in November 2016","chapters":[{"id":"d2b6d668-4d29-5c50-b65d-7467cbcce2dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47f9af8d-8bda-55a3-bf81-eb75a7c4f02a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a0ece3e-fa44-5ecd-9f55-ac17384d960c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"44a5b5f9-fc8e-5024-87e3-a7e42dca3dd9","slug":"changes","fullItemName":"Changes"},{"id":"48757ec5-731a-57fd-8e39-d2cdf918179a","slug":"update","fullItemName":"Update"}]},{"id":"53ae2089-f545-5b24-99c5-a9fc620ea575","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ffff20e4-5bc5-5c3b-bb59-858dba2fcf8d","slug":"goals","fullItemName":"Goals"},{"id":"16f85d1d-aec7-5173-9e0b-7d9456bdf3a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12a41d5f-f447-5a64-868a-7648c7de9355","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5de2a0f3-a77d-5244-a401-dbd2cbcfefb3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fc893fb4-51ec-5705-8dff-c7fba1969646","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cc1cc5c4-df13-5e74-bde0-9f625ec4d1cf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"02e2bd4f-75cd-5b59-9a81-c06d3bcf4d2f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a8eb5f7-6691-505b-bd86-9620102057a3","slug":"definition","fullItemName":"Definition"},{"id":"b756c83a-dcc0-5792-b3f9-fa9416929ce3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"488c0ab1-f1c0-5fbf-bd1e-e327181c2e1f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b62a5aae-0dc3-5ac0-a1b1-d3ca0a7969ac","slug":"complications","fullItemName":"Complications"}]},{"id":"9336c0e7-d5d3-5dd6-99fd-50610ced96e1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dd5a2bec-36ce-58c0-b0f1-4ec5d4d17c21","slug":"when-to-suspect-sickle-cell-disease","fullItemName":"When to suspect sickle cell disease"},{"id":"bdbf4e2a-7a0c-5a2e-8b9c-4a9c661409ef","slug":"diagnosis-of-sickle-cell-disease","fullItemName":"Diagnosis of sickle cell disease"},{"id":"68746f0d-607a-5db5-8949-a87a4ed29328","slug":"when-to-suspect-an-acute-sickle-cell-crisis","fullItemName":"When to suspect an acute sickle cell crisis"},{"id":"ed48dbda-a404-50cf-a290-86fafcdb9908","slug":"assessment-of-acute-crisis","fullItemName":"Assessment of acute crisis"}]},{"id":"221fb88b-b951-5835-b282-ed218b637ff0","fullItemName":"Management","slug":"management","subChapters":[{"id":"e76854fe-5d45-5d85-8591-5712daa7e4d9","slug":"screening","fullItemName":"Scenario: Screening"},{"id":"1da4d393-99a4-51c1-b354-f1742b9d8b1f","slug":"management-sickle-cell-crisis","fullItemName":"Scenario: Management - sickle cell crisis"},{"id":"2bf8553c-1641-5bdc-bbc3-2615ddc5b84c","slug":"management-chronic-complications","fullItemName":"Scenario: Management - chronic complications"},{"id":"4493185d-8907-5325-a195-a7cd7039bd68","slug":"prevention-of-complications","fullItemName":"Scenario: Prevention of complications"},{"id":"2aeac855-0e31-598c-804d-41c8d9bc643f","slug":"management-sickle-cell-trait","fullItemName":"Scenario: Management - sickle cell trait"},{"id":"5b85ac92-9286-564f-88fb-ec37a6f4102e","slug":"contraception","fullItemName":"Scenario: Contraception"}]},{"id":"a424bf70-c56c-54a4-a2e2-019ab7c27c69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"515607d5-c2e2-5a4c-8d83-1bb5e320badf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2148be5b-6502-5e45-b86b-e552aa3226fd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"acc3b704-7f3d-51ed-869e-38e0309c53e5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a46384b-d43c-536a-9a17-4b8953d8457a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"46873f42-ab32-5894-b2fe-429a4e62161b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1dd24310-b8ac-5381-b51a-ca1f6c178d72","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7405fe0a-8432-5e64-9fe0-4d112fd89232","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"221fb88b-b951-5835-b282-ed218b637ff0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"f774ba26-3900-5e4b-8b0c-ee6175121f81","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 00c0d408-cfc8-415a-ab1e-345710305b07 --><h3>How should I manage people with sickle cell trait? </h3><!-- end field 00c0d408-cfc8-415a-ab1e-345710305b07 -->","summary":null,"htmlStringContent":"<!-- begin item dc1bc1eb-6667-4bd5-ae52-f842f32634f5 --><!-- begin field 1b846f20-73ba-4355-b40e-d434695bd9b0 --><p><strong>As sickle cell trait is usually asymptomatic, management consists mainly of providing appropriate advice.</strong></p><ul><li><strong>Explain to the person with sickle cell traits and/or their family/carers that:</strong><ul><li>They should very rarely have symptoms. However, they are at risk of a vaso-occlusive episode if they become oxygen deprived. They should therefore:<ul><li>Avoid high altitudes, such as travelling in an unpressurized aircraft.</li><li>Inform the anaesthetist that they are sickle cell carriers, if they are going to have an anaesthetic.</li></ul></li><li>They have 1 in 2 chance of passing the sickle haemoglobin gene to their child. If the other parent is also a carrier, there is a 1 in 4 chance that their child will have sickle cell disease.</li><li>It is important to have malaria prophylaxis if they will be visiting an area where malaria is endemic. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/malaria-prophylaxis/\">Malaria prophylaxis for more information</a><strong>.</strong></li></ul></li><li><strong>Refer children and adults with haematuria.</strong></li><li><strong>Refer children and adults urgently if they present with symptoms suggestive of </strong><a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/background-information/complications/#chronic-complications\">renal medullary cancer</a><strong> — haematuria, weight loss, loin pain, fever, and abdominal pain.</strong><ul><li>Refer using the suspected cancer pathway referral (for an appointment within 2 weeks).</li></ul></li></ul><!-- end field 1b846f20-73ba-4355-b40e-d434695bd9b0 --><!-- end item dc1bc1eb-6667-4bd5-ae52-f842f32634f5 -->","subChapters":[{"id":"ceb18a4f-ce35-5a27-a2c2-61339e339146","slug":"basis-for-recommendation-e1f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c9159779-2fbf-43fb-9e10-33408ffedc92 --><h4>Basis for recommendation</h4><!-- end field c9159779-2fbf-43fb-9e10-33408ffedc92 -->","summary":null,"htmlStringContent":"<!-- begin item e1fdb1e8-f540-4172-b50e-a5146db41615 --><!-- begin field c9d9efb1-6b59-416c-8eaf-a554b183193b --><h5>Advice on avoiding hypoxia</h5><ul><li>These recommendations are based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care </em>published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by<em> </em>the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>], and in a textbook on a haemoglobin disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Weatherall, 2010</a>].</li><li>A review article cited a few reported cases of splenic infarction at altitudes over 10,000 feet in people with the sickle cell trait [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sears, 1978</a>].</li></ul><h5>Malaria prophylaxis</h5><ul><li>Expert opinion in the guidelines <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>] and <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] is that people travelling to endemic malaria areas should receive full prophylaxis according to current recommendations for that country. This statement is true for all people, including those with sickle cell trait.</li></ul><p><strong>Referral if there is haematuria or </strong><strong>clinical features of renal medullary cancer</strong></p><ul><li>Expert opinion in a review article is that medullary infarction may lead to renal papillary necrosis in people with sickle cell trait, and rarely, renal medullary cancer may occur in people with the sickle cell trait [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Claster and Vichinsky, 2003</a>].</li><li>The clinical features of renal medullary cancer are based on expert opinion in the <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</li></ul><!-- end field c9d9efb1-6b59-416c-8eaf-a554b183193b --><!-- end item e1fdb1e8-f540-4172-b50e-a5146db41615 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}